Literature DB >> 23415570

Controversies and priorities in amyotrophic lateral sclerosis.

Martin R Turner1, Orla Hardiman, Michael Benatar, Benjamin R Brooks, Adriano Chio, Mamede de Carvalho, Paul G Ince, Cindy Lin, Robert G Miller, Hiroshi Mitsumoto, Garth Nicholson, John Ravits, Pamela J Shaw, Michael Swash, Kevin Talbot, Bryan J Traynor, Leonard H Van den Berg, Jan H Veldink, Steve Vucic, Matthew C Kiernan.   

Abstract

Two decades after the discovery that 20% of familial amyotrophic lateral sclerosis (ALS) cases were linked to mutations in the superoxide dismutase-1 (SOD1) gene, a substantial proportion of the remainder of cases of familial ALS have now been traced to an expansion of the intronic hexanucleotide repeat sequence in C9orf72. This breakthrough provides an opportunity to re-evaluate longstanding concepts regarding the cause and natural history of ALS, coming soon after the pathological unification of ALS with frontotemporal dementia through a shared pathological signature of cytoplasmic inclusions of the ubiquitinated protein TDP-43. However, with profound clinical, prognostic, neuropathological, and now genetic heterogeneity, the concept of ALS as one disease appears increasingly untenable. This background calls for the development of a more sophisticated taxonomy, and an appreciation of ALS as the breakdown of a wider network rather than a discrete vulnerable population of specialised motor neurons. Identification of C9orf72 repeat expansions in patients without a family history of ALS challenges the traditional division between familial and sporadic disease. By contrast, the 90% of apparently sporadic cases and incomplete penetrance of several genes linked to familial cases suggest that at least some forms of ALS arise from the interplay of multiple genes, poorly understood developmental, environmental, and age-related factors, as well as stochastic events.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23415570      PMCID: PMC4565161          DOI: 10.1016/S1474-4422(13)70036-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  123 in total

1.  Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis.

Authors:  Gwenaëlle Douaud; Nicola Filippini; Steven Knight; Kevin Talbot; Martin R Turner
Journal:  Brain       Date:  2011-11-10       Impact factor: 13.501

2.  Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models.

Authors:  Benjamin C Cheah; Steve Vucic; Arun V Krishnan; Robert A Boland; Matthew C Kiernan
Journal:  Amyotroph Lateral Scler       Date:  2011-01

3.  The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study.

Authors:  Julie Phukan; Marwa Elamin; Peter Bede; Norah Jordan; Laura Gallagher; Susan Byrne; Catherine Lynch; Niall Pender; Orla Hardiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-08-11       Impact factor: 10.154

Review 4.  Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better?

Authors:  John Douglas Mitchell; Pauline Callagher; Joyce Gardham; Catriona Mitchell; Mandy Dixon; Robert Addison-Jones; Wendy Bennett; Mary R O'Brien
Journal:  Amyotroph Lateral Scler       Date:  2010-06-22

5.  Design, power, and interpretation of studies in the standard murine model of ALS.

Authors:  Sean Scott; Janice E Kranz; Jeff Cole; John M Lincecum; Kenneth Thompson; Nancy Kelly; Alan Bostrom; Jill Theodoss; Bashar M Al-Nakhala; Fernando G Vieira; Jeyanthi Ramasubbu; James A Heywood
Journal:  Amyotroph Lateral Scler       Date:  2008

6.  Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Authors:  Brian C Kraemer; Bin Zhang; James B Leverenz; James H Thomas; John Q Trojanowski; Gerard D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-18       Impact factor: 11.205

7.  Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.

Authors:  Albert C Ludolph; Caterina Bendotti; Eran Blaugrund; Bastian Hengerer; Jean-Philippe Löffler; Joanne Martin; Vincent Meininger; Thomas Meyer; Saliha Moussaoui; Wim Robberecht; Sean Scott; Vincenzo Silani; Leonard H Van Den Berg
Journal:  Amyotroph Lateral Scler       Date:  2007-08

8.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

9.  Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia.

Authors:  Han-Xiang Deng; Wenjie Chen; Seong-Tshool Hong; Kym M Boycott; George H Gorrie; Nailah Siddique; Yi Yang; Faisal Fecto; Yong Shi; Hong Zhai; Hujun Jiang; Makito Hirano; Evadnie Rampersaud; Gerard H Jansen; Sandra Donkervoort; Eileen H Bigio; Benjamin R Brooks; Kaouther Ajroud; Robert L Sufit; Jonathan L Haines; Enrico Mugnaini; Margaret A Pericak-Vance; Teepu Siddique
Journal:  Nature       Date:  2011-08-21       Impact factor: 49.962

10.  Genetic overlap between apparently sporadic motor neuron diseases.

Authors:  Marka van Blitterswijk; Lotte Vlam; Michael A van Es; W-Ludo van der Pol; Eric A M Hennekam; Dennis Dooijes; Helenius J Schelhaas; Anneke J van der Kooi; Marianne de Visser; Jan H Veldink; Leonard H van den Berg
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

View more
  175 in total

1.  Lou Gehrig and the ALS split hand.

Authors:  Matthew C Kiernan; Martin R Turner
Journal:  Neurology       Date:  2015-12-01       Impact factor: 9.910

2.  ALS-linked protein disulfide isomerase variants cause motor dysfunction.

Authors:  Ute Woehlbier; Alicia Colombo; Mirva J Saaranen; Viviana Pérez; Jorge Ojeda; Fernando J Bustos; Catherine I Andreu; Mauricio Torres; Vicente Valenzuela; Danilo B Medinas; Pablo Rozas; Rene L Vidal; Rodrigo Lopez-Gonzalez; Johnny Salameh; Sara Fernandez-Collemann; Natalia Muñoz; Soledad Matus; Ricardo Armisen; Alfredo Sagredo; Karina Palma; Thergiory Irrazabal; Sandra Almeida; Paloma Gonzalez-Perez; Mario Campero; Fen-Biao Gao; Pablo Henny; Brigitte van Zundert; Lloyd W Ruddock; Miguel L Concha; Juan P Henriquez; Robert H Brown; Claudio Hetz
Journal:  EMBO J       Date:  2016-02-11       Impact factor: 11.598

Review 3.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

Review 4.  Acetyltransferases (HATs) as targets for neurological therapeutics.

Authors:  Anne Schneider; Snehajyoti Chatterjee; Olivier Bousiges; B Ruthrotha Selvi; Amrutha Swaminathan; Raphaelle Cassel; Frédéric Blanc; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 5.  FTD and ALS--translating mouse studies into clinical trials.

Authors:  Lars M Ittner; Glenda M Halliday; Jillian J Kril; Jürgen Götz; John R Hodges; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2015-05-05       Impact factor: 42.937

6.  Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans.

Authors:  Daniela Mariosa; John D Beard; David M Umbach; Rino Bellocco; Jean Keller; Tracy L Peters; Kelli D Allen; Weimin Ye; Dale P Sandler; Silke Schmidt; Fang Fang; Freya Kamel
Journal:  Am J Epidemiol       Date:  2017-03-01       Impact factor: 4.897

7.  Body mass index delineates ALS from FTD: implications for metabolic health.

Authors:  R M Ahmed; E Mioshi; J Caga; M Shibata; M Zoing; L Bartley; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2014-06-24       Impact factor: 4.849

8.  Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis.

Authors:  Danilo B Medinas; Pablo Rozas; Francisca Martínez Traub; Ute Woehlbier; Robert H Brown; Daryl A Bosco; Claudio Hetz
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

Review 9.  Gene Therapy Strategies to Restore ER Proteostasis in Disease.

Authors:  Vicente Valenzuela; Kasey L Jackson; Sergio P Sardi; Claudio Hetz
Journal:  Mol Ther       Date:  2018-04-07       Impact factor: 11.454

10.  Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients.

Authors:  Paloma Gonzalez-Perez; Ute Woehlbier; Ru-Ju Chian; Peter Sapp; Guy A Rouleau; Claire S Leblond; Hussein Daoud; Patrick A Dion; John E Landers; Claudio Hetz; Robert H Brown
Journal:  Gene       Date:  2015-04-22       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.